dimanche 15 novembre 2026
RechercherExplore
fr.via.news
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· May 23, 2026

ROST Q1 Deep Dive: Broad-Based Sales Gains and Tariff Risks Shape Outlook

View original at finance.yahoo.com
ROST Q1 Deep Dive: Broad-Based Sales Gains and Tariff Risks Shape Outlook Off-price retail company Ross Stores (NASDAQ:ROST) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 20.6% year on year to $6.01 billion…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Ross Stores will use a variety of sourcing and pricing levers to navigate tariff headwinds and remains focused on maintaining its value proposition while adjusting merchandise flows

    60% confidence

  • Potential profitability pressures stemming from trade policy uncertainty are a risk factor for the remainder of fiscal 2026

    60% confidence

  • CEO James Conroy highlighted momentum in cosmetics and consistent performance from the dd's DISCOUNTS brand in Q1 CY2026

    60% confidence

  • Q1 CY2026 performance was driven by opportunistic inventory buys, flexible merchandising, sequential sales improvements, and effective execution in inventory management

    60% confidence

  • Geographic performance was balanced across the country, with the Southeast emerging as the best-performing region during Q1 CY2026

    60% confidence

  • Ross Stores is withdrawing its previously provided annual guidance due to too many unknown variables limiting visibility into the second half of the fiscal year

    60% confidence
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,997
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,997 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
ROST Q1 Deep Dive: Broad-Based Sales Gains and Tariff Risks Shape Outlook: Source | Via News | fr.via.news